Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company’s Chief Scientific Officer.

https://ir.korrobio.com/news-releases/news-release-details/korro-appoints-biotech-industry-veteran-loic-vincent-phd-chief